Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1200-1207

  Vinson, Gavin P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CORTICOSTEROID; GLUCOCORTICOID; HYDROCORTISONE;

ADIPOCYTE; ARTICLE; ENDOCRINE FUNCTION; ENZYME ACTIVITY; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYNDROME X;

ADIPOCYTES; ADRENAL CORTEX HORMONES; ANGIOTENSIN II; ANIMALS; DIABETES MELLITUS, TYPE 2; FEEDBACK, BIOCHEMICAL; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; RENIN-ANGIOTENSIN SYSTEM;

EID: 33947628277     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.065     Document Type: Article

References (119)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Reaven G.M. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol 9 (1998) 387-406
3. Reaven G.M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 44 (1993) 121-131
4. Abbasi F., Brown Jr. B.W., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity insulin resistance and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
5. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14 (1991) 1132-1143
6. Bjorntorp P., and Rosmond R. Visceral obesity and diabetes. Drugs 58 1 (1999) 13-18 discussion 75-82
7. Stern M.P. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44 (1995) 369-374
8. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
9. Bjorntorp P., and Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann NY Acad Sci 892 (1999) 297-307
10. Bjorntorp P., and Rosmond R. The metabolic syndrome - a neuroendocrine disorder?. Br J Nutr 83 1 (2000) S49-S57
11. Sowers J.R., Khoury S., Standley P., Zemel P., and Zemel M. Mechanisms of hypertension in diabetes. Am J Hypertens 4 (1991) 177-182
12. Sowers J.R., and Khoury S. Diabetes and hypertension: a review. Prim Care 18 (1991) 509-524
13. Tait J.F., and Tait S.A.S. Insulin, the renin-angiotensin-aldosterone system and blood pressure. Perspect Biol Med 40 (1997) 246-259
14. Bonner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol 24 2 (1994) S39-S49
15. Haynes W.G., Morgan D.A., Walsh S.A., Sivitz W.I., and Mark A.L. Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 25 (1998) 65-69
16. Badman M.K., and Flier J.S. The gut and energy balance: visceral allies in the obesity wars. Science 307 (2005) 1909-1914
17. Trujillo M.E., and Scherer P.E. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
18. Girard J. Is leptin the link between obesity and insulin resistance?. Diabetes Metab 23 3 (1997) 16-24
19. Chen Y.E., Fu M., Zhang J., et al. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm 66 (2003) 157-188
20. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat Med 10 (2004) 355-361
21. Granneman J., Skoff R., and Yang X. Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J Neurosci Res 51 (1998) 563-573
22. Camejo G. PPAR agonists in the treatment of insulin resistance and associated arterial disease. Int J Clin Pract Suppl (2003) 36-44
23. Lebovitz H.E. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl (2003) 18-27
24. Guerre-Millo M., Rouault C., Poulain P., et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50 (2001) 2809-2814
25. Hevener A.L., He W., Barak Y., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9 (2003) 1491-1497
26. He W., Barak Y., Hevener A., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 100 (2003) 15712-15717
27. Yamauchi T., Waki H., Kamon J., et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108 (2001) 1001-1013
28. Cock T.A., Houten S.M., and Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5 (2004) 142-147
29. Huang K.C., Lin R.C., Kormas N., et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int J Obes Relat Metab Disord 28 (2004) 470-475
30. Sivitz W.I., Walsh S.A., Morgan D.A., Thomas M.J., and Haynes W.G. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138 (1997) 3395-3401
31. Poitout V., Rouault C., Guerre-Millo M., Briaud I., and Reach G. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans. Endocrinology 139 (1998) 822-826
32. Poitout V., Rouault C., Guerre-Millo M., and Reach G. Does leptin regulate insulin secretion?. Diabetes Metab 24 (1998) 321-326
33. Rosmond R., Chagnon Y.C., Holm G., et al. Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab 85 (2000) 3126-3131
34. Gabriely I., Ma X.H., Yang X.M., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes 51 (2002) 2951-2958
35. Kadowaki T., Hara K., Yamauchi T., Terauchi Y., Tobe K., and Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228 (2003) 1111-1117
36. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
37. Choi K.M., Lee J., Lee K.W., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 61 (2004) 75-80
38. Garaulet M., Viguerie N., Porubsky S., et al. Adiponectin gene expression and plasma values in obese women during very-low-calorie diet Relationship with cardiovascular risk factors and insulin resistance. J Clin Endocrinol Metab 89 (2004) 756-760
39. Xydakis A.M., Case C.C., Jones P.H., et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 89 (2004) 2697-2703
40. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
41. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278 (2003) 2461-2468
42. Waki H., Yamauchi T., Kamon J., et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology (2004)
43. Steppan C.M., and Lazar M.A. The current biology of resistin. J Intern Med 255 (2004) 439-447
44. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
45. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 20 (2004) 295-304
46. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100 (2003) 14211-14216
47. Phillips M.I., Speakman E.A., and Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 43 (1993) 1-20
48. Bader M., Peters J., Baltatu O., Muller D.N., Luft F.C., and Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 79 (2001) 76-102
49. Mulrow P.J. Adrenal renin: regulation and function. Front Neuroendocrinol 13 (1992) 47-60
50. Vinson G.P., and Ho M.M. The adrenal renin/angiotensin system in the rat. Horm Metab Res 30 (1998) 355-359
51. Baltatu O., and Bader M. Brain renin-angiotensin system Lessons from functional genomics. Neuroendocrinology 78 (2003) 253-259
52. Nushiro N., Ito S., and Carretero O.A. Renin release from microdissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int 38 (1990) 426-431
53. Ingelfinger J.R., Zuo W.M., Fon E.A., Ellison K.E., and Dzau V.J. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85 (1990) 417-423
54. Chai S.Y., Zhuo J., and Mendelsohn F.A. Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittelforschung 43 (1993) 214-221
55. Harris R.C., and Cheng H.F. The intrarenal renin-angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 4 (1996) 2-7
56. Vinson G.P., Saridogan E., Puddefoot J.R., and Djahanbakhch O. Tissue renin-angiotensin systems and reproduction. Hum Reprod 12 (1997) 651-662
57. Leung P.S., and Sernia C. The renin-angiotensin system and male reproduction: new functions for old hormones. J Mol Endocrinol 30 (2003) 263-270
58. Unger T., and Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol 65 (1990) 3I-10I
59. Stock P., Liefeldt L., Paul M., and Ganten D. Local renin-angiotensin systems in cardiovascular tissues - localization and functional-role. Cardiology 86 (1995) 2-8
60. Xiao F., Puddefoot J.R., Barker S., and Vinson G.P. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 44 (2004) 340-345
61. Tahmasebi M., Puddefoot J.R., Inwang E.R., and Vinson G.P. The tissue renin-angiotensin system in human pancreas. J Endocrinol 161 (1999) 317-322
62. Lam K.Y., and Leung P.S. Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol 146 (2002) 567-572
63. Tahmasebi M., Puddefoot J.R., Inwang E.R., Goode A.W., Carpenter R., and Vinson G.P. Transcription of the prorenin gene in normal and diseased breast. Eur J Cancer 34 (1998) 1777-1782
64. Sramek S.J., Wallow I.H.L., Day R.P., and Ehrlich E.N. Ocular renin-angiotensin - immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophth Vis Sci 29 (1988) 1749-1752
65. Danser A.H.J., Derkx F.H.M., Admiraal P.J.J., Deinum J., Dejong P.T.V.M., and Schalekamp M.A.D.H. Angiotensin levels in the eye. Invest Ophth Vis Sci 35 (1994) 1008-1018
66. Wagner J., Danser A.H.J., Derkx F.H.M., et al. Demonstration of renin messenger-rna, angiotensinogen messenger-rna, and angiotensin-converting enzyme messenger-rna expression in the human eye - evidence for an intraocular renin-angiotensin system. Brit J Ophthalmol 80 (1996) 159-163
67. Crandall D.L., Herzlinger H.E., Saunders B.D., and Kral J.G. Developmental aspects of the adipose-tissue renin-angiotensin system - therapeutic implications. Drug Dev Res 32 (1994) 117-125
68. Schling P., Mallow H., Trindl A., and Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 23 (1999) 336-341
69. Karlsson C., Lindell K., Ottosson M., Sjostrom L., Carlsson B., and Carlsson L.M. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 83 (1998) 3925-3929
70. Engeli S., Schling P., Gorzelniak K., et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-825
71. Massiera F., Bloch-Faure M., Ceiler D., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. Faseb J 15 (2001) 2727-2729
72. Strazzullo P., and Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 13 (2004) 325-332
73. Gorzelniak K., Engeli S., Janke J., Luft F.C., and Sharma A.M. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 20 (2002) 965-973
74. Harte A.L., McTernan P.G., McTernan C.L., et al. Insulin increases angiotensinogen expression in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5 (2003) 462-467
75. Pantanetti P., Garrapa G.G., Mantero F., Boscaro M., Faloia E., and Venarucci D. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens 26 (2004) 387-398
76. Jasik M., Kasperskadworak A., and Czyzyk A. Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non- insulin-dependent) diabetes and in hypertensive non-diabetics. Diabetes Res Clin Pr 33 (1996) 59-66
77. Sharma A.M., Janke J., Gorzelniak K., Engeli S., and Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611
78. Marrero M.B., Fulton D., Stepp D., and Stern D.M. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24 (2004) 2009-2013
79. Sechi L.A., Griffin C.A., Zingaro L., Valentin J.P., Bartoli E., and Schambelan M. Effects of angiotensin II on insulin receptor binding and m RNA levels in normal and diabetic rats. Diabetologia 40 (1997) 770-777
80. Sharma A.M. Is there a rationale for angiotensin blockade in the management of obesity hypertension?. Hypertension 44 (2004) 12-19
81. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
82. Darimont C., Vassaux G., Ailhaud G., and Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 135 (1994) 2030-2036
83. Jones B.H., Standridge M.K., and Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 138 (1997) 1512-1519
84. Fliser D., Schaefer F., Schmid D., Veldhuis J.D., and Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 30 (1997) 1156-1161
85. Gross F., Brunner H., and Ziegler M. Renin-angiotensin system, aldosterone and sodium balance. Recent Prog Horm Res 21 (1965) 119-177
86. Aguilera G., and Catt K.J. Regulation of aldosterone secretion by the renin-angiotensin system during sodium restriction in rats. Proc Natl Acad Sci USA 75 (1978) 4057-4061
87. Vinson G.P., Whitehouse B.J., and Hinson J.P. The adrenal cortex (1992), Prentice-Hall, Englewood Heights, NJ
88. Lebrethon M.C., Jaillard C., Defayes G., Begeot M., and Saez J.M. Human cultured adrenal fasciculata-reticularis cells are targets for angiotensin-II: effects on cytochrome P450 cholesterol side-chain cleavage, cytochrome P450 17 alpha-hydroxylase, and 3 beta-hydroxysteroid-dehydrogenase messenger ribonucleic acid and proteins and on steroidogenic responsiveness to corticotropin and angiotensin-II. J Clin Endocrinol Metab 78 (1994) 1212-1219
89. Lebrethon M.C., Jaillard C., Naville D., Begeot M., and Saez J.M. Regulation of corticotropin and steroidogenic enzyme mRNAs in human fetal adrenal cells by corticotropin, angiotensin-II and transforming growth factor beta 1. Mol Cell Endocrinol 106 (1994) 137-143
90. Breidert M., Bornstein S.R., Ehrhart-Bornstein M., Scherbaum W.A., and Holst J.J. Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. Peptides 17 (1996) 287-292
91. Ishizuka T., Daidoh H., Morita H., et al. ACTH-induced cortisol secretion is mediated by cAMP and PKC in various adrenocortical adenomas. Endocr J 44 (1997) 661-670
92. Rabano M., Pena A., Brizuela L., Macarulla J.M., Gomez-Munoz A., and Trueba M. Angiotensin II-stimulated cortisol secretion is mediated by phospholipase D. Mol Cell Endocrinol 222 (2004) 9-20
93. Tanabe A., Naruse M., Arai K., et al. Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. Horm Metab Res 30 (1998) 490-495
94. Lavery G.G., Ronconi V., Draper N., et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42 (2003) 123-129
95. Stewart P.M., and Edwards C.R. The cortisol-cortisone shuttle and hypertension. J Steroid Biochem Mol Biol 40 (1991) 501-509
96. Livingstone D.E., Jones G.C., Smith K., et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141 (2000) 560-563
97. Livingstone D.E., Kenyon C.J., and Walker B.R. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 167 (2000) 533-539
98. Engeli S., Bohnke J., Feldpausch M., et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 12 (2004) 9-17
99. Masuzaki H., Yamamoto H., Kenyon C.J., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112 (2003) 83-90
100. Paterson J.M., Morton N.M., Fievet C., et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101 (2004) 7088-7093
101. Hermanowski-Vosatka A., Gerhold D., Mundt S.S., et al. PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun 279 (2000) 330-336
102. Berger J., Tanen M., Elbrecht A., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276 (2001) 12629-12635
103. Ambrosi B., Dall'Asta C., Cannavo S., et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151 (2004) 173-178
104. Della Bruna R., Ries S., Himmelstoss C., and Kurtz A. Expression of cardiac angiotensin II AT1 receptor genes in rat hearts is regulated by steroids but not by angiotensin II. J Hypertens 13 (1995) 763-769
105. Shelat S.G., Flanagan-Cato L.M., and Fluharty S.J. Glucocorticoid and mineralocorticoid regulation of angiotensin II type 1 receptor binding and inositol triphosphate formation in WB cells. J Endocrinol 162 (1999) 381-391
106. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
107. Aubert J., Darimont C., Safonova I., Ailhaud G., and Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J 328 Pt 2 (1997) 701-706
108. Atzmon G., Yang X.M., Muzumdar R., Ma X.H., Gabriely I., and Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34 (2002) 622-628
109. Xiao F., Puddefoot J.R., and Vinson G.P. The expression of renin and the formation of angiotensin II in bovine aortic endothelial cells. J Endocrinol 164 (2000) 207-214
110. Yip R.G., and Goodman H.M. Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions. Endocrinology 140 (1999) 1219-1227
111. Djurhuus C.B., Gravholt C.H., Nielsen S., Pedersen S.B., Moller N., and Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 286 (2004) E488-E494
112. Kaschina E., and Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12 (2003) 70-88
113. Pitt B., Stier Jr. C.T., and Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4 (2003) 164-168
114. Young M., and Funder J.W. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in doc/salt rats. Endocrinology 145 (2004) 3153-3157
115. Reynolds R.M., Walker B.R., Syddall H.E., et al. Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 86 (2001) 245-250
116. Ward A.M., Syddall H.E., Wood P.J., Chrousos G.P., and Phillips D.I. Fetal programming of the hypothalamic-pituitary-adrenal (HPA) axis: low birth weight and central HPA regulation. J Clin Endocrinol Metab 89 (2004) 1227-1233
117. Phillips D.I., Barker D.J., Fall C.H., et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome?. J Clin Endocrinol Metab 83 (1998) 757-760
118. Hatakeyama H., Miyamori I., Takeda Y., Yamamoto H., and Mabuchi H. The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 40 (1996) 639-645
119. Takeda Y., Miyamori I., Yoneda T., et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81 (1996) 2797-2800